Corneal Collagen Crosslinking

UV-A light treatment with riboflavin to strengthen the cornea and halt progression of keratoconus and corneal ectasia.

Overview

Corneal collagen crosslinking (CXL) is a treatment designed to halt the progression of keratoconus and other corneal ectatic disorders. It works by strengthening the collagen fibres within the cornea, preventing further weakening and bulging.

The treatment involves applying riboflavin (vitamin B2) drops to the cornea, followed by controlled exposure to UV-A light. This combination creates new chemical bonds between collagen fibres, significantly increasing corneal rigidity and stability.

CXL does not reverse existing corneal changes or typically improve vision directly. Its primary goal is stabilisation—stopping the condition from getting worse. For young patients with progressive keratoconus, early crosslinking can prevent the need for corneal transplant later in life.

The standard "epi-off" Dresden protocol, which involves removing the surface epithelium to allow better riboflavin penetration, remains the gold standard with the most evidence supporting its efficacy.

What This Means for You

Halts or significantly slows keratoconus progression
May reduce or eliminate the need for corneal transplant
One-time treatment with long-lasting effect
Preserves the natural cornea
Well-established safety profile with extensive research data

Ms. Menassa's Approach

Ms. Menassa carefully assesses each keratoconus patient with corneal topography and tomography to determine whether the condition is progressive and whether crosslinking is appropriate. Not all keratoconus patients need treatment—stable disease may simply be monitored.

She uses the proven Dresden protocol (epi-off technique) because it has the strongest evidence base. The procedure is performed with careful attention to corneal thickness monitoring and UV exposure parameters.

Importantly, she sets realistic expectations: crosslinking aims to stabilise, not cure. Many patients will still need contact lenses or glasses after treatment, and some may eventually need corneal transplant despite crosslinking. Honest discussion of outcomes is fundamental to her approach.

Is This Right for You?

Patients with documented progressive keratoconus
Young keratoconus patients at higher risk of progression
Those with post-LASIK ectasia or other corneal ectatic disorders
Patients with corneal thickness adequate for safe treatment (typically >400 microns)

Frequently Asked Questions

Crosslinking is primarily a stabilisation treatment. While some patients experience modest vision improvement, this is not the main goal. You will likely still need glasses or contact lenses after treatment.

Progression is detected by comparing corneal scans over time—typically 6-12 months apart. Signs include increasing corneal steepness, thinning, or worsening vision despite updated glasses. Ms. Menassa will assess your scans carefully.

Yes, most patients can return to contact lens wear once the cornea has healed—typically 1-3 months after treatment. Rigid gas permeable or scleral lenses often provide the best vision for keratoconus patients.

Studies show crosslinking halts progression in approximately 90-95% of cases. Some patients experience continued slow progression and may need repeat treatment or eventually require corneal transplant.